95882-33-0

Basic information

• Product Name: 3-CYCLOPENTYL-3-OXO-PROPIONITRILE
• Synonyms: 3-CYCLOPENTYL-3-OXO-PROPIONITRILE;b-Oxo-cyclopentanepropanenitrile;3-Cyclopentyl-3-oxopropanenitrile;β-Oxo-cyclopentanepropanenitrile;Cyclopentanepropanenitrile, .beta.-oxo-;3-Cyclopentyl-3-oxo-propionitrile - C10418
• CAS NO: 95882-33-0
• Molecular Formula: C₈H₁₁NO
• Molecular Weight: 137.18
• Mol File: 95882-33-0.mol

Chemical Properties

• Boiling Point: 229.5 °C at 760 mmHg
• Flash Point: 92.6 °C
• Appearance: /
• Density: 1.056 g/cm³
• PKA: 9.77±0.20(Predicted)
• CAS DataBase Reference: 3-CYCLOPENTYL-3-OXO-PROPIONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CYCLOPENTYL-3-OXO-PROPIONITRILE(95882-33-0)
• EPA Substance Registry System: 3-CYCLOPENTYL-3-OXO-PROPIONITRILE(95882-33-0)

Safety Data

• Hazardous Substances Data: 95882-33-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Cyclopentyl-3-oxo-propionitrile is utilized as a key intermediate in organic synthesis for the production of various organic compounds. Its ability to participate in multiple chemical reactions allows for the creation of a wide array of products, contributing to the diversity of organic chemistry.
Used in Pharmaceutical Research and Development:
In the pharmaceutical industry, 3-Cyclopentyl-3-oxo-propionitrile serves as an essential intermediate in the synthesis of drugs and pharmaceutical compounds. Its unique structure and reactivity make it a promising candidate for the development of new medications, potentially leading to advancements in healthcare and treatment options.
Used in the Development of New Materials:
Due to its distinctive chemical properties, 3-Cyclopentyl-3-oxo-propionitrile has potential applications in the development of innovative materials. Its reactivity and structural features can be harnessed to create new materials with unique properties, expanding the horizons of material science and technology.
Used in Chemical Process Development:
3-CYCLOPENTYL-3-OXO-PROPIONITRILE's versatility in chemical reactions also makes it a candidate for the development of new chemical processes. By exploring its reactivity, researchers can potentially discover more efficient or novel methods for producing a variety of chemical products, thereby enhancing industrial processes and chemical manufacturing techniques.

InChI:InChI=1S/C8H11NO/c9-6-5-8(10)7-3-1-2-4-7/h7H,1-5H2

Upstream product

• 4630-80-2 methyl cyclopentane carboxylate 
• 75-05-8 acetonitrile 
• 3400-45-1 cyclopentanecarboxylic acid 
• 5453-85-0 ethyl cyclopentanecarboxylate 

Downstream Products

• 264209-16-7 5-cyclopentyl-2H-pyrazol-3-ylamine 
• 1188908-81-7 2-(2-cyclopentyl-1,3-dioxolan-2-yl)acetonitrile 
• 1188908-82-8 C₁₀H₁₈N₂O₃ 
• 1188908-80-6 1-(5-cyclopentylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea 
• 1188909-39-8 1-(3-cyclopentylisoxazol-5-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea 
• 1012879-78-5 3-cyclopentylisoxazol-5-amine 
• 1188909-40-1 phenyl 3-cyclopentylisoxazol-5-ylcarbamate 
• 1188908-83-9 5-cyclopentylisoxazol-3-amine 
• 1247949-64-9 phenyl 5-cyclopentylisoxazol-3-ylcarbamate 
• 1146629-83-5 (R)-3-(4-bromo-1H-pyrazol-1-yl)-3-cyclopentylpropanecarbonitrile 

Relevant articles and documents

Dual-inhibitors of N-Myc and AURKA as potential therapy for neuroendocrine prostate cancer

Resistance to androgen-receptor (AR) directed therapies is, among other factors, associated with Myc transcription factors that are involved in development and progression of many cancers. Overexpression of N-Myc protein in prostate cancer (PCa) leads to its transformation to advanced neuroendocrine prostate cancer (NEPC) that currently has no approved treatments. N-Myc has a short half-life but acts as an NEPC stimulator when it is stabilized by forming a protective complex with Aurora A kinase (AURKA). Therefore, dual-inhibition of N-Myc and AURKA would be an attractive therapeutic avenue for NEPC. Following our computer-aided drug discovery approach, compounds exhibiting potent N-Myc specific inhibition and strong anti-proliferative activity against several N-Myc driven cell lines, were identified. Thereafter, we have developed dual inhibitors of N-Myc and AURKA through structure-based drug design approach by merging our novel N-Myc specific chemical scaffolds with fragments of known AURKA inhibitors. Favorable binding modes of the designed compounds to both N-Myc and AURKA target sites have been predicted by docking. A promising lead compound, 70812, demonstrated low-micromolar potency against both N-Myc and AURKA in vitro assays and effectively suppressed NEPC cell growth.

MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN

Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising the Same

The present disclosure relates to a novel phenylpyridine derivative represented by Chemical Formula 1 and a pharmaceutical composition comprising the same, and the compound according to the present disclosure can be usefully used for the prevention or treatment of autoimmune diseases or cancers.

PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS

Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.

A green, economical synthesis of β-ketonitriles and trifunctionalized building blocks from esters and lactones

The acylation of the acetonitrile anion with lactones and esters in ethereal solvents was successfully exploited using inexpensive KOt-Bu to obtain a variety of β-ketonitriles and trifunctionalized building blocks, including useful O-unprotected diols. It was discovered that lactones react to produce the corresponding derivatized cyclic hemiketals. Furthermore, the addition of a catalytic amount of isopropanol, or 18-crown-6, was necessary to facilitate the reaction and to reduce side-product formation under ambient conditions.

Preparation method of ruxolitinib intermediate (3R)-3-(4-Br-1H-pyrazole-1-yl)-cyclopentyl propanenitrile

The present invention relates to a preparation method of ruxolitinib intermediate (3R)-3-(4-Br-1H-pyrazole-1-yl)-cyclopentyl propanenitrile, and the method comprises the following steps: (1) synthesisof 3-oxo-3-cyclopentyl propionitrile (II); (2) synthesis of (S)-3-cyclopentyl-3-hydroxypropionitrile (III); (3) synthesis of (3R)-3-(4-nitro-1H-pyrazole-1-yl)-cyclopentyl propionitrile (IV); (4) synthesis of (3R)-3-(4-amino-1H-pyrazole-1-yl)-cyclopentyl propionitrile (V); and (5) (3R)-3-(4-Br-1H-pyrazole-1-yl)-cyclopentyl propanenitrile (VI). The method has the advantages of good stereoselectivity, low cost, mild reaction conditions, no requirement on harsh reaction such as high temperature, high pressure and ultra-low temperature.

Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy

We synthesized a library of aminopyrazole analogs to systematically explore the hydrophobic pocket adjacent to the hinge region and the solvent exposed region of cyclin dependent kinases. Structure-activity relationship studies identified an optimal substitution for the hydrophobic pocket and analog 24 as a potent and selective CDK2/5 inhibitor.

A Russo advantage for Nepal synthesis of intermediates method (by machine translation)

The invention relates to a Russo advantage for Nepal synthesis of intermediates method, first of all by the cyclopentane carboxylic acid methyl ester and acetonitrile catalytic reaction preparation 3 - cyclopentyl - 3 - oxo third nitrile, then 3 - cyclopentyl - 3 - oxo third nitrile enzyme catalytic asymmetric reduction to generate chiral alcohols (S) - 3 - cyclopentyl - 3 - hydroxy propionitrile; (S) - 3 - cyclopentyl - 3 - hydroxy propionitrile by the Mitsunobu reaction and 4 - bromine pyrazole coupling get Russo advantage for Nepal intermediate (3R) - 3 - (4 - bromo - 1H - pyrazole - 1 - yl) - 3 - cyclopentane isopropyl amine; the synthesis method has the short route, the cost is low, mild condition, stereoselectivity is good, is suitable for the industrial production of the advantages. (by machine translation)

AURORA KINASE INHIBITORS

Disclosed herein inter alia are compositions and methods useful in the treatment of cancer and for modulating the activity of Aurora A kinase and/or a Myc family protein.

HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.